热休克蛋白融合蛋白抗肿瘤免疫佐剂的初步筛选

Primary screening of antitumor immunoadjuvants combined with heat shock fusion protein

目的:筛选一种具有增强热休克融合蛋白HSP-MUC1抗肿瘤作用的免疫佐剂。方法:将HSP-MUC1与新型CpG ODN或人源性IFNα2b混合后皮下注射MUC1阳性荷瘤小鼠,各分4组,分别是磷酸盐缓冲液(PBS)、HSP-MUC1、CpG ODN(hIFNα2b)及HSP-MUC1+CpG ODN(HSP-MUC1+hIFNα2b)。观察各组肿瘤发生率及肿瘤体积变化。结果:HSP-MUC1+CpG ODN组与PBS组及HSP-MUC1组比较小鼠的肿瘤发生率及肿瘤重量均降低(P<0.05);单独应用CpG ODN组表现出与HSP-MUC1+CpG ODN组相似的抑瘤作用,与PBS组及HSP-MUC1组比较,肿瘤发生率及肿瘤的重量均降低(P<0.05);而HSP-MUC1+IFNα2b组与PBS组及HSP-MUC1组比较,小鼠肿瘤发生率及肿瘤重量差异均无显著性(P>0.05)。结论:CpG ODN是一种能增强HSP-MUC1抗肿瘤作用的免疫佐剂,人源性IFNα2b则不能增强HSP-MUC1的抗肿瘤活性。

Objective To screen one kind of antitumor immunoadjuvant that could enhance the anti-tumor activity of heat shock fusion protein （HSP-MUC1）. Methods MUCl-positive tumor bearing mice were subcutaneously injected by HSP-MUC1 combined with a novel CpG ODN or hIFNα2b, four groups were set up respectively as PBS, HSP-MUC1, CpG ODN （IFNα2b） and HSP-MUC1＋CpG ODN （HSP-MUC1 ＋IFNα2b）. The tumor incidence and tumor volume in various groups were observed and calculated. Results The tumor incidence and tumor weight of mice in HSP-MUC1＋CpG ODN group were lower than those in PBS group and HSP-MUC1 group （P〈0. 05）; CpG ODN alone also displayed the similar anti-tumor effect as HSP-MUC1＋CpG ODN, it could decrease the tumor incidence and tumor weight of mice compared with PBS and HSP-MUC1 （P〈0. 05） ; And the tumor incidence and tumor weight of mice in HSP-MUC1 ＋ hIFNα2b group had no difference with those in PBS group and HSP-MUC1 group （P〉0.05）. Conclusion CpG ODN could enhance the anti-tumor activity of HSP- MUC1 but need to be further determined for its optimal injection time; and human IFNα2b could not enhance the anti-tumor activity of HSP-MUC1.